Kalorama: Stem Cell Therapies Hold Hope for Alzheimer's Treatments

NEW YORK, Nov. 21, 2014 /PRNewswire/ -- Because Alzheimer's disease kills brain cells, some scientists believe that stem cells, which have the ability to regenerate brain and other similar cells, may one day be able to prevent or reverse the course of Alzheimer's disease. Even though the disease and the course of treatment is not well understood, there are several developers tackling this area of stem cell therapy and the promise it holds in treating, or perhaps even curing, Alzheimer's disease. Kalorama Information believes that given this potential there is an opportunity for a future market. Kalorama's Stem Cell Therapeutics Markets conducts in-depth research into the stem cell arena by assessing current technology performance, new developments, pricing trends and government positions on the topic.

"Stem cells have become effective tools in blood diseases, musculoskeletal diseases, digestive disorders and many other areas," said Melissa Elder, author of Kalorama's report. "This offers hope that a stem cell approach to Alzheimer's may one day be successful."

Alzheimer's disease is a progressive and irreversible loss of nerve cells in brain areas responsible for controlling thought, memory and language. There are currently about 35 million persons living with Alzheimer's disease worldwide, of which 5 million reside in the U.S., 10 million live in Europe and more than 2 million live in Japan. The United States Centers for Disease Control and Prevention (CDC) estimates that in 2010 the costs of Alzheimer's disease could range as high as $200 billion.

The healthcare market researcher's report takes a combination approach to the stem cell market – using both a bottom-up model and comparing data with a top-down analysis – to determine market size and market forecasts. Over the next several years, as researchers introduce a growing variety of technologies, products and services based upon stem cells, revenues related to stem cell therapies will increase dramatically. In addition to potential Alzheimer's therapies, new therapeutic applications of stem cells could potentially be realized in all of the following disease segments:

• Blood and Blood-Forming Organs
• Circulatory System
• Endocrine and Metabolic System and Immunity Disorders
• Eye
• Gastrointestinal System
• Musculoskeletal System and Connective Tissue Disorders
• Neoplasms
• Nervous System
• Respiratory System
• Skin and Subcutaneous Tissues

There are more than 4,000 research projects underway for stem cell therapies throughout the world. About a dozen companies worldwide are currently evaluating stem cell therapies in late stage clinical trials. Companies discussed in this report include those which have registered trials in Phase I through Phase III development. These include:

• Aastrom Biosciences
• Advanced Cell Technology
• Anterogen
• Antria
• apceth
• Arteriocyte
• Athersys
• Baxter
• BioCardia
• Bioheart
• BrainStorm Cell
• Capricor
• Celgene
• Cytomedix
• Cytori
• Gamida Cell
• GlaxoSmithKline
• ISCO
• Intrexon
• ISTO
• Medipost
• Mesoblast
• NeoStem
• Neuralstem
• Pharmicell
• Pluristem
• ReNeuron
• SanBio
• StemCells
• Stemedica Cell
• Stempeutics
• Targazyme
• TiGenix
• ViaCyte

Stem Cell Therapeutics Markets can be found at KI: http://www.kaloramainformation.com/redirect.asp?progid=86867&productid=8436333.  

About Kalorama Information -- Kalorama Information, a division of MarketResearch.com, supplies the latest in independent medical market research in diagnostics, biotech, pharmaceuticals, medical devices and healthcare; as well as a full range of custom research services. We routinely assist the media with healthcare topics. Follow us on Twitter, LinkedIn and our blog.

Contact:
Bruce Carlson
(212) 807-2622
[email protected] 
www.KaloramaInformation.com

Logo - http://photos.prnewswire.com/prnh/20140801/132634

SOURCE Kalorama Information